Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may improve cardiovascular health by reducing appetite and weight through central nervous system effects, decreasing hepatic steatosis, and lowering triglyceride and LDL-C levels [137]. The gene discussed is GLP1R; the disease is fatty liver disease.